Peter Heerma - 31 Jan 2025 Form 4 Insider Report for Travere Therapeutics, Inc. (TVTX)

Signature
/s/ Elizabeth E. Reed, Attorney-in-Fact
Issuer symbol
TVTX
Transactions as of
31 Jan 2025
Net transactions value
-$103,940
Form type
4
Filing time
04 Feb 2025, 20:30:15 UTC
Previous filing
23 Jan 2025
Next filing
12 Feb 2025

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction TVTX Common Stock Award $0 +21,500 +20% $0.000000 127,874 31 Jan 2025 Direct F1
transaction TVTX Common Stock Sale $103,940 -5,166 -4% $20.12 122,708 03 Feb 2025 Direct F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction TVTX Employee stock option (right to buy) Award $0 +58,000 $0.000000 58,000 31 Jan 2025 Common Stock 58,000 $20.46 Direct F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Each restricted stock unit represents a contingent right to receive one share of the Common Stock of the Issuer.
F2 Represents the number of shares required to be sold by the Reporting Person to cover the tax withholding obligation in connection with the settlement of vested restricted stock units. This sale is mandated by the Issuer's election under its equity incentive plans to require the Reporting Person to fund this tax withholding obligation by completing a "sell to cover" transaction with a brokerage firm designated by the Issuer. This sale does not represent a discretionary trade by the Reporting Person.
F3 One-fourth of the shares subject to the stock option vest and become exercisable on the first anniversary of the date of grant, and the remaining shares vest in 36 equal monthly installments thereafter.